Private Equity Poised To Take Control Of Opella But Sanofi Will Retain Sizable Stake

Control of Sanofi Consumer Healthcare – recently rebranded as Opella – may soon pass to US private-equity firm CD&R but the French firm looks set to retain a substantial stake in a business which has some big Rx-to-OTC switches in the pipeline.

• Source: shutterstock

Sanofi is negotiating a deal to sell a controlling stake in its Consumer Healthcare division enabling the French firm to retain a substantial share of the business.

A year on from Sanofi announcing its intention to separate Consumer Healthcare, US private-equity firm Clayton, Dubilier & Rice is seeking to acquire a 50% controlling stake in a business which generated sales of €5.18bn ($5.67bn) in 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.